JMT103

DRUG4 trials

Sponsors

Shanghai JMT-Bio Inc.

Conditions

Glucocorticoid Induced OsteoporosisHypercalcemia of MalignancyImaging Examination Shows at Least One Site With Bone Metastases From Soild TumorsPostmenopausal Osteoporosis

Phase 1

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Shanghai JMT-Bio Inc.Hypercalcemia of Malignancy

Start: 2020-01-24End: 2021-12-31Target: 17Updated: 2019-12-13

Phase 2

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Shanghai JMT-Bio Inc.Postmenopausal Osteoporosis

Start: 2022-04-21End: 2024-03-31Target: 200Updated: 2022-07-18

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Shanghai JMT-Bio Inc.Glucocorticoid Induced Osteoporosis

Start: 2022-06-15End: 2023-06-01Target: 231Updated: 2022-05-31

Phase 3

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Not yet recruitingNCT06221072

Shanghai JMT-Bio Inc.Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Start: 2024-04-05End: 2028-05-31Target: 1360Updated: 2024-01-24

Related Papers

Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.

2025-07-04

Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

Frontiers in Oncology2022-08-059 citations